Ignacio Garrido-Laguna, MD
Ignacio Garrido-Laguna, MD is an assistant professor of oncology at the University of Utah School of Medicine and a Huntsman Cancer Institute (HCI) investigator. At HCI, he sees patients with gastrointestinal cancers and patients enrolled in Phase 1 trials. His primary research interest is pancreatic ductal adenocarcinoma. His work in patient derived xenografts has shown that the stroma is involved in resistance to gemcitabine. At HCI, Ignacio is part of an effort to identify druggable genetic aberrations in patients referred to their phase 1 unit. The hypothesis is that matching patients to drugs targeting genetic aberrations present in their tumors may increase response to targeted therapies. Ignacio’s work has shown that coactivation of MAPK pathway in patients with colorectal cancer harboring PIK3CA mutations may contribute to resistance to PI3K/mTOR inhibitors in this disease. Ignacio received his medical degree from the School of Medicine of Universidad de Navarra in Pamplona (Spain). He finished his internship and residency in medical oncology at Hospital Universitario 12 de Octubre in Madrid, Spain. He completed his training with a postdoctoral fellowship in the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and a clinical fellowship in the Phase I program at the University of Texas MD Anderson Cancer Center.